Post-gemcitabine advanced pancreatic cancer patients have limited treatment options.
Head-to-head comparisons of common oxaliplatin-based regimens are not available.
Randomized oxaliplatin- and irinotecan-based chemotherapy trials were reviewed.
Differences noted in study design, patient/treatment characteristics, and outcomes.
Evaluated studies were dissimilar, precluding an indirect treatment comparison.